The Efficiency of Transarterial Chemoembolization with Drug-Eluting Beads in Hepatocellular Carcinoma
Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010; 7:448–58.
Venook AP, Papandreou C, Furuse J, de Guevara LL. The ıncidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15:5–13.
Bruix J, Sherma M. AASLD Practice Guideline. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-2.
Forner A RM, Rodrigruez de Lope C, Bruix J. Current Strategy for Staging and Treatment: the BCLC Update and Future Prospects Semin Liver Dis 2010; 30:61–74.
Huppert P. Current concepts in transarterial chemoem- bolization of hepatocellular carcinoma. Abdom Imaging 2011; 36:677-83.
Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52:762-73.
Kalva SP, Thabet A, Wicky S. Recent advances in transar- terial therapy of primary and secondary liver malignan- cies. Radiographics 2008; 28:101-17.
Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: ef- ficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46:474–81.
Hong K, Khwaja A, Liapi E, et al. New intra-arterial drug delivery system for the treatment of liver cancer: pre- clinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006; 12:2563–7.
Poon RT, Tso WK, Pang RW, et al. A phase I/II trial of che- moembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007; 5:1100–18.
Okuda K, Ohtsuki T, Obata H, et al. Natural history of he- patocellular carcinoma and prognosis in relation to treat- ment. Study of 850 patients. Cancer 1985; 56:918-28.
The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and he- patocellular carcinoma. Hepatology 2000; 31:840-5.
Bruix J, Sherman M, Llovet JM, et al. Clinical manage- ment of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421–30.
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649–55.
Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diag- nostic radiologists. Br J Radiol 2001; 74:983-6.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statis- tics. CA Cancer J Clin 2005; 55:74-108.
Llovet JM, Bruix J. Systematic review of random- ized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37:429–42.
Martin RC, Rustein L, Enguix DP, et al. Hepatic arterial in- fusion of Doxorubicin loaded microsphere for treatment of hepatocellular cancer: a multi-institutional registry. J Am Coll Surg 2011; 213:493-500.
Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodoL chemoembolization for un- resectable hepatocellular carcinoma. Hepatology 2002; 35:1164–71.
Marelli L, Stigliano R, Triantos C, et al. Cardiovascular and Inervent Radiol, Transarterial therapy for hepato- cellular carcinoma: which technique is more effective? Asystematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30:6-25.
Lewis AL, Gonzalez MV, Lloyd AW, et al. DC bead: in vi- tro characterization of a drug-delivery device for tran- sarterial chemoembolization. J Vasc Interv Radiol 2006; 17:335–42.
Malagari K, Alexopoulou E, Chatzimichail K, et al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 2008; 33:512–9.
Lammer J, Malagari K, Vogl T, et al. Prospective random- ized study of doxorubicin eluting- bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33:41-52.
Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemo- embolization (TACE) and chemoembolization with doxo- rubicin drug eluting beads (DEB) for unresectable hepato- celluar carcinoma (HCC). J Surg Oncol 2010; 101:476-80.
Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing che- moembolization with doxorubicin drug-eluting beads: a preliminary study. HPB (Oxford) 2010; 12:174-80.
Reyes DK, Vossen JA, Kamel IR, et al. Single-center phase II trial of transarterial chemoembolization with drug- eluting beads for patients with unresectable hepatocel- lular carcinoma: initial experience in the United States. Cancer J 2009; 15:526–32.
Sadick M, Haas S, Loehr M, et al. Application of DC beads in hepatocellular carcinoma: clinical and radiological re- sults of a drug delivery device for transcatheter super- selective arterial embolization. Onkologie 2010; 33:31-7.
Liapi E, Geschwind JF. Intra arterial therapies for hepa- tocellular carcinoma: where do we stand? Ann Surg Oncol 2010; 17:1234-46.
Malagari K, Pomoni M, Spyridopoulos TN, et al. Safety Profile of Sequential Transcatheter Chemoembolization with DC Bead: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol 2011; 34:774-85.
Kettenbach J, Stadler A, Katzler IV, et al. Drug-loaded mi- crospheres for the treatment of liver cancer: review of cur- rent results. Cardiovasc Intervent Radiol 2008; 31:468-76.